Enanta Pharmaceuticals (ENTA) Assets Average (2013 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Assets Average came in at $322.1 million in Q1 2026, down 4.08% YoY from $335.8 million in Q1 2025, and up 5.57% on a QoQ basis from $305.1 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Assets Average (2013 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 14 years of Assets Average data on file, last reported at $322.1 million in Q1 2026.
- Quarterly Assets Average fell 4.08% year-over-year to $322.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322.1 million (down 4.08% YoY) and the FY2025 annual result came in at $328.7 million, down 21.64% from the prior year.
- Assets Average improved to $322.1 million in Q1 2026, from $305.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $478.7 million in Q3 2023 to a low of $290.9 million in Q3 2025.
- A 5-year average of $375.1 million and a median of $380.3 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average climbed 25.88% — and 2025, when it declined 24.98%.
- Tracing ENTA's Assets Average over 5 years: stood at $361.5 million in 2022, then rose by 23.21% to $445.4 million in 2023, then retreated by 18.58% to $362.6 million in 2024, then fell by 15.86% to $305.1 million in 2025, then gained by 5.57% to $322.1 million in 2026.
- The last three Assets Average figures came in at $322.1 million (Q1 2026), $305.1 million (Q4 2025), and $290.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 305.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 305.79 Mn |
| Mar 31, 2026 | 322.10 Mn |
| Dec 31, 2025 | 305.12 Mn |
| Sep 30, 2025 | 290.88 Mn |
| Jun 30, 2025 | 312.01 Mn |
| Mar 31, 2025 | 335.82 Mn |
| Dec 31, 2024 | 362.65 Mn |
| Sep 30, 2024 | 387.74 Mn |
| Jun 30, 2024 | 406.19 Mn |
| Mar 31, 2024 | 421.03 Mn |
| Dec 31, 2023 | 445.39 Mn |
| Sep 30, 2023 | 478.72 Mn |
| Jun 30, 2023 | 410.81 Mn |
| Mar 31, 2023 | 336.99 Mn |
| Dec 31, 2022 | 361.47 Mn |
| Sep 30, 2022 | 380.31 Mn |
| Jun 30, 2022 | 396.02 Mn |
| Mar 31, 2022 | 423.71 Mn |
| Dec 31, 2021 | 439.69 Mn |
| Sep 30, 2021 | 444.61 Mn |